1
. The mechanisms that contribute to tumour heterogeneity (FIG. 1) are now starting to be understood. Glioblastoma (GBM) is a highly hetero geneous tumour 2 and was one of the first cancers to be profiled through The Cancer Genome Atlas (TCGA) project 3 (supervised by the National Institute of Health (NIH)), making it one of the most genomically well characterized types of cancer. Mutations in genes that occur at frequencies ≥5% above baseline levels are also likely to have been identified in genome wide profiling studies 4 and so further contribute to the rich data set that can be used to understand GBM heterogeneity.
Receptor tyrosine kinases (RTKs) are crucial regulators of the growth factor sig nalling that controls cellular proliferation, metabolism and survival in response to environmental cues 5, 6 . Therefore, it is not surprising that genetic alterations of RTKs, including those in the epidermal growth factor receptor (EGFR), have major roles in the development and progression of GBM 7 .
RTKs have a remarkably heterogeneous cell ular pattern within individual tumours 8, 9 .
In this Opinion article, we focus on EGFR amplification and mutations in GBM (see REF. 10 for a detailed and uptodate summary of integrated GBM genomics). We also highlight the causes and conse quences of intratumoural EGFR hetero geneity in GBM, focus on the general mechanisms that drive this feature, link these mechanisms with specific molecular events and examine their impact on signal transduction, cellular metabolism and resistance to EGFRtargeted therapy.
Tumour heterogeneity
The term tumour heterogeneity can be used to describe multiple forms of tumour vari ability, including intertumoural mutational pattern variation, intratumoural histologi cal variation and intratumoural mutational polyclonality. In GBM, intertumoural muta tional patterns are relatively stereotypical and are less heterogeneous than the range of mutations observed in many other types of cancer 4, 11 . By contrast, individual GBM tumours display striking histological vari ation 12 . The full extent of intratumoural mutational polyclonality in GBM tumours is not yet known but, at present, the amount of intratumoural mutational heterogeneity seems to be similar to the amount that is observed in most cancer types.
In cancer, spontaneous somatic muta tions, combined with sequential selection for aggressive subclones (that is, cells that can survive and/or proliferate in a compromised microenvironment), drive the growth of sin gle cancer cells into complex, heterogeneous tumour masses 13 . In this paradigm, which is known as clonal evolution, new mutations are produced with increasing frequency as the tumour progresses, which makes late stage cancer progressively more difficult to treat. Much recent data, including next generation sequencing data, support the clonal evolution model as a major underpin ning of tumour progression, heterogeneity and drug resistance [14] [15] [16] [17] [18] [19] [20] [21] (FIG. 1a) . However, these same data show that clonal evolution in human solid tumours is not a linear pro cess in which only one clone dominates as the tumour evolves.
Heterogeneity is also shaped by the local microenvironment. First, direct cell-cell interactions between inflammatory, stro mal, endothelial 22 and tumour cells, as well as autocrine and paracrine responses to secreted factors 23 , all impart selection pressures within the tumour microenviron ment. Second, physical features, includ ing neuroanatomical structures and the proximity of the tumour to blood vessels and/or the leptomeninges, can also affect nutrient and oxygen levels in tumour cells. Therefore, regional heterogeneity can develop as tumour cells experience distinct selection pressures in different parts of the tumour (FIG. 1b) . Third, cooperation between tumour subclones may also maintain intratumoural mutational hetero geneity [24] [25] [26] (FIG. 1c) . Last, cancer therapy also shapes tumour heterogeneity by either expanding or collapsing tumour cell sub populations depending on the treatment (discussed below).
Nongenetic mechanisms also have an important role in tumour heterogeneity. The cancer stem cell model suggests that a hierarchical organization of tumours exists in which cancer cells give rise to both tumori genic and nontumorigenic prog eny -a process that generates phenotypic cellular heterogeneity [27] [28] [29] . Based on mecha nisms that are poorly understood 22, 27, 28 , the relative proportion of tumorigenic versus Abstract | As tumours evolve, the daughter cells of the initiating cell often become molecularly heterogeneous and develop different functional properties and therapeutic vulnerabilities. In glioblastoma (GBM), a lethal form of brain cancer, the heterogeneous expression of the epidermal growth factor receptor (EGFR) poses a substantial challenge for the effective use of EGFR-targeted therapies. Understanding the mechanisms that cause EGFR heterogeneity in GBM should provide better insights into how they, and possibly other amplified receptor tyrosine kinases, affect cellular signalling, metabolism and drug resistance. (FIG. 1d) . The fac tors that make a cell tumorigenic or non tumorigenic remain unclear, but epigenetic mechanisms that influence differentiation states 23 , may activate oncogenic pathways that can lead to cellular dedifferentiation 30, 31 and result in the genetic alteration of a bona fide stem cell 27 might all have a role. At present, the role of cellular dedifferentiation in gliomagenesis remains unclear 32 . Some genetic mouse models indicate that neural stem cell and/or progenitor cell popula tions, such as the subventricular zone of the brain, are more likely to undergo malignant transformation in response to oncogenic perturbations than differentiated cells, such as the astrocytes and neurons of the cerebral cortex or striatum [33] [34] [35] . By contrast, other experimental mouse models indicate that mature and highly differentiated cells can also undergo malignant transformation in response to oncogenic perturbations 31, 36, 37 . Neural stem cells, astrocytes and even differ entiated neurons were capable of generating malignant gliomas in response to lentiviral transduction of oncogenes, and showed high expression of stem and progenitor cell markers, regardless of the cell of origin 31 . Future studies will be needed to further determine the role of dedifferentiation in gliomagenesis.
RTK amplification and mutation in GBM
The genomic 'portrait' of GBM is rich and can be viewed from multiple perspectives, each yielding decidedly different views as to the essential molecular features and poten tial drug targets. In this Opinion article, we consider that the genetic alteration of growth factor receptor signalling pathways is an essential component of most adult GBMs. The Pan Cancer project of TCGA, the goals of which include the identification of action able driver mutations through the com parative analysis of 3,000 tumours across 12 cancer types, similarly concluded that genetically altered RTKs, and their down stream effectors, are the most abundant targetable driver mutations in GBM 38 . This is also consistent with mouse models of GBM, in which the reconstitution of the genetically altered components of growth factor signal ling pathways, in the same molecular context as in clinical samples, recreates histologically identical GBMs 36, 37 . Thus, independent, converging and compelling lines of evidence indicate that the RTK lesions detected in GBM, and their associated biochemical alterations, are crucial driver events in GBM development.
Importantly, not all GBMs are driven by RTK alterations. Identifying potential muta tions in shared nodes of convergence that are downstream of RTKs in adult GBMssuch as isocitrate dehydrogenase 1 (IDH1) mutations, tumour protein p53 (TP53) muta tions in lowgrade gliomas and epigenomic mutations in paediatric GBMs -may provide crucial new insights into the funda mental molecular underpinnings of GBM pathogenesis.
Heterogeneity of RTK mutations in primary GBM. To date, integrated exome sequencing and DNA copy number analysis of 251 GBMs has been carried out through TCGA, providing a bird's eye view of the diversity of RTK genetic alteration 7 . This survey focused on primary GBMs -de novo GBMs that did not arise from lower grade gliomas. This form of GBM is, unfortunately, the most common clinical presentation of the disease, representing up to 95% of cases in some epidemiological studies 39 . RTK amplifications and/or muta tions had occurred in 66% of the primary GBM samples that were tested by TCGA. Amplifications and/or mutations in EGFR were the only RTK lesions observed in 50% of all de novo primary GBMs. EGFR genetic alterations also coexist with other RTK lesions, but this occurs in only a small pro portion (7%) of tumours. Therefore, EGFR genetic alterations -including mutations, rearrangements, alternative splicing and focal amplifications -are the dominant RTK lesions in GBM, occurring in 57% of tumours 7 and, overall, are the most com mon oncogene alteration in these tumours. Amplification of platelet derived growth factor receptor alpha polypeptide (PDGFRA) occurs in 13% of GBMs, and nearly half of these tumours also contain amplifications and/or mutations in EGFR 7 (FIG. 2a) . MET amplifications and fibroblast growth factor receptor (FGFR) mutations, including fusion genes 40, 41 , occur in approx imately 2% of the GBMs that have been analysed to date (FIG. 2a) .
RTK alterations usually coexist with mutations that activate other core regulatory pathways, including downstream compo nents of growth factor receptor signalling pathways 7 . A frequency distribution of the coexistence of mutations and copy number alterations stratified by the RTK genotype demonstrates the frequent cooccurrence of mutations in PI3K and deletion of PTEN, as well as the cooccurrence of mutations and/or deletion of cyclindependent kinase inhibitor 2A (CDKN2A; encoding both INK4A and ARF) with all of the detectable RTK alterations 7 . This is consistent with the required cooperation of multiple core path ways for tumour formation in genetically engineered mouse models of GBM 3, 7, 8 . Thus, the genomic portrait suggests a surprisingly straightforward picture: EGFR is the dominant, but not the exclusive, RTK lesion in primary GBMs; EGFR altera tions are usually the sole RTK lesions; and RTK lesions usually occur in the context of other PI3Kpathway activating alterations and in the presence of CDKN2A loss and inactivation.
Focusing on RTK heterogeneity. The RTK genetic alterations in primary GBM that are presented in FIG. 2 do not look heterogene ous; however, closer inspection reveals a substantial amount of RTK diversity (FIG. 3) . Glioblastoma multiforme, the former name of GBM, was used to describe the strik ing cellular heterogeneity of the disease. Immunohistochemical staining of RTK alterations -such as EGFR variant III (EGFRvIII), which is the most common EGFR mutation in GBM and is charac terized by the deletion of exons 2-7 that results in an inframe deletion variant that has a truncated extracellular domain with ligandindependent constitutive activity 12 (BOX 1) -shows similar cellular heteroge neity [42] [43] [44] [45] [46] . Consequently, DNA and RNA sequencing of bulk tumours provide only a limited insight into the RTK distribution among the many different cell subpopula tions within the tumour. Therefore, the extent of RTK heterogeneity has, until recently, been poorly quantified. Single cell DNA 47 and RNA 48 sequencing, and the bulk analysis of DNA and RNA that has been extracted from different regions of a tumour 49, 50 , has begun to shed much needed light on the extent of intratumoural RTK heterogeneity in GBM.
RTK co-amplification. Fluorescent in situ hybridization using EGFR and PDGFRA DNA probes shows that some GBMs contain two different amplified RTKs 51, 52 . In these rare tumours, most of the GBM cells contain either EGFR or PDGFRA amplifications, but not both, and usually the tumour cells containing PDGFRA amplifications are the minority population 51 . It is tempting to specu late that this pattern could arise from biclonal evolution, or that one of the RTK amplicons is progressively lost because it does not con fer a sufficient growth advantage. However, the unequal segregation of amplified alleles, clonal cooperation and regional microenvi ronmental selection pressures 51 might also contribute to this genetic heterogeneity. This example highlights the challenge of trying to infer clonal hierarchies from single molecular 'snapshots' of a tumour (FIG. 3a) .
EGFR amplification with multiple mutations. A new singlecell sequencing approach has been used to identify unique, nonoverlapping subclonal alterations in GBM 47, 53 . In 71% of the samples that were studied, EGFR amplifications coexisted with at least one of a diverse range of EGFR vari ants, including structural alterations and/or missense extracellular domain mutations. In one particularly insightful example, up to 32 possible different clonal combina tions, based on five distinct EGFR genomic lesions, were found 47 .
In depth singlenucleus sequencing analysis of two additional GBMs, integrated with bulk sequencing of the tumours, showed that the intratumoural heterogeneity of EGFR amplification and mutation arose through multiple routes 47, 53 . In the first case, all of the tumour cells contained amplified wildtype EGFR and amplified EGFRvIII, but the levels of each varied dramatically among the tumour cells. EGFRvIII DNA can be located outside chromosomes in double minute DNA fragments 2, 7, 54 at levels that can vary from cell to cell owing to their unequal segregation, which thus contributes to the intratumoural heterogeneity of EGFRvIII DNA levels (discussed below). In the sec ond case, amplified wildtype EGFR and four additional amplified EGFR variants (BOX 1) were evident in the tumour, and these mutations were mutually exclusive, which suggests that the convergent evolution of independent EGFR mutants had occurred. These rare variants within the tumour were not detected by nextgeneration sequencing of the bulk tumour, raising the possibility that RTK intratumoural heterogeneity, at least with respect to EGFR (and perhaps other RTKs), might be even greater than is currently thought.
Transcription of amplified and mutated
RTKs. The transcription of RTK mutants introduces an additional source of intra tumoural heterogeneity (FIG. 3b) (FIG. 3b) .
Regional selection. Two recent studies indi cate that RTK amplification, and the expres sion of amplified and mutated transcripts, can vary substantially in different parts of the same GBM. In the first study, a surgical intraoperative mapping scheme was used to collect spatially distinct regions from 11 samples of GBM, and they carried out copy number and transcriptome analyses of samples, including some samples from patients who were repeatedly biopsied over time, to assess intratumoural heterogene ity 49 . Different regions of the same tumour showed distinctive molecular signatures, and this was used to assemble a potential path of clonal evolution. In the second study 50 , RNA sequencing analysis of GBM biopsies that were taken with the aid of magnetic resonance imaging showed highly variable transcriptional patterns, including those of RTKs, in different regions of the tumour. These initial findings suggest that regions of the tumour could differ because of variations in the tumour microenvironment.
All of the studies discussed above begin to highlight the extent of regional intratumoural molecular heterogeneity in GBM. However, the full extent of regional heterogeneity of amplified and mutated RTKs remains unclear. Trying to reconstruct clonal hierarchies from molecular snapshots that are derived from either DNA copy number and DNA sequenc ing or RNA sequencing of bulk tumour sam ples remains a substantial challenge. Future studies that integrate singlecell RNA or DNAsequencing analysis from different regions of the same tumour, and that take into consideration protein expression levels, including how they change over time and in response to various treatments, will probably provide new insights into the regional intra tumoural RTK heterogeneity and potentially into the different selection pressures that contribute to this (FIG. 3c) .
Mechanisms of RTK heterogeneity
What are the specific molecular mechanisms by which the intratumoural heterogeneity of RTKs develops in GBM? Answering this question has been difficult because, unlike secondary GBMs that develop from lower grade gliomas and for which a sequence of mutations is beginning to emerge 55 , primary de novo GBMs are highly malignant on initial clinical presentation. Thus, directly observing the molecular sequence of events that drive GBM formation has not been pos sible in tumour samples from patients or in genetic mouse models.
One approach that has been adopted by some investigators uses mathematical model ling to infer the order of multistep mutational events in the genesis of primary GBMs. Based on the assumption that selfrenewing cells can accumulate cancercausing muta tions through a stochastic process, dynamic mathematical models are constructed and the results are compared to the frequencies of mutations that are observed in TCGA data 56 . This approach has been recently used to infer that aneuploidy involving chromosomes 7 and 10 is an early event that is followed by CDKN2A or TP53 loss. Overexpression of PDGFA on chromosome 7 was implicated as a driving event in GBM formation because PDGFα overexpression is sufficient for GBM formation in a genetic mouse model 57 . The mathematical model also predicted that EGFR focal amplifications and mutations were late events. However, alternative muta tional paths are likely to be relevant to GBM formation and progression.
Consistent with the clonal selection model (FIG. 1a) , deletion and mutation of CDKN2A and/or TP53 could contribute to genome instability, thereby providing vari ous cells with different mutations that will be subject to selective pressures. The capacity of cells to tolerate a high mutational load might occur as a result of mutations that alter cell cycle regulation and/or senescence, enabling cells bearing damaged DNA to continue to proliferate (FIG. 4a) . TCGA GBM data indicate that CDKN2A deletion or loss of expression was detected in 61% of the GBMs for which whole exome and copy number data were available. This loss was enriched in GBMs with EGFR amplifications, and/or mutations, and was found in 74% of tumours (FIG. 2b) . This high frequency is consistent with genetic mouse models showing that combined EGFRvIII expression and CDKN2A loss are sufficient to transform mouse astro cytes into GBMs 36 . Reanalysis of TCGA data 7 shows that deletions and point muta tions in TP53 are greatly enriched in GBMs with amplified EGFR and/or mutated EGFR that lack CDKN2A lesions (41%) compared with GBMs with EGFR amplifications and CDKN2A lesions (14%), suggesting an alter native source of genome instability that ena bles the development and clonal selection of EGFR amplification and mutation. Consistent 43 , but most GBM cells seem to express only one single-mutant RTK transcript 44 . At present, the underlying mechanisms are not understood. EGFR, epidermal growth factor receptor; EGFRvIII, epidermal growth factor receptor variant III; PDGFRA, platelet derived growth factor receptor alpha polypeptide.
with this, only 6% of the GBMs with EGFR amplifications and/or mutations contained both CDKN2A and TP53 genetic lesions 7 . The molecular mechanisms that underlie the aneuploidy of chromosome 7 -an event that is presumed to occur early in GBM develop ment 57 -the focal amplification, structural rearrangements and mutations of EGFR on chromosome 7, and whether these events are linked, remain unclear, but a number of molecular mechanisms are possible 58 .
Once EGFR amplifications, gene rearr angements and/or mutations have occurred, EGFR heterogeneity might be generated and maintained through a series of com plimentary interlacing mechanisms. First, EGFRvIII strongly promotes tumour cell proliferation in a cellautonomous man ner 59, 60 , therefore these cells are likely to have a proliferative advantage (FIG. 4) . Second, the clonal cooperation between populations of GBM cells bearing different EGFR vari ants might maintain a heterogeneous state, and one study has shown that even a small number of GBM cells expressing EGFRvIII can contribute to the growth of wildtype EGFR GBMs through a novel interleukin 6 (IL6)dependent pathway 26 . Last, unequal segregation of EGFRvIII alleles on extra chromosomal DNA provides a compelling mechanism for introducing and maintaining EGFRvIII heterogeneity, especially because levels of EGFRvIII DNA could potentially be increased or decreased as an adaptive response to changes in the tumour environ ment 2 . Thus, RTK heterogeneity could be generated and maintained through clonal selection, clonal cooperation, regulation of extrachromosomal DNA and regional selection, resulting in a cellular composi tion that maximizes tumour growth (FIG. 4) Functional impact of RTK heterogeneity Until recently, it has been difficult to assess the effect of intratumoural RTK hetero geneity on cell signalling, metabolism and behaviour, including response to treatment. Recent technical advances [61] [62] [63] have made it possible to quantify signalling differences and to assess variations in proliferative and apoptotic indices (through Ki67 and termi nal deoxy nucleotidyl transferase dUTP nick end labelling (TUNEL) assays, respectively) of distinct subpopulations of cells within a tumour and thus to begin to examine the functional consequences of RTK hetero geneity 2 . For example, EGFRvIII + GBM cells are more proliferative and undergo less apoptotic cell death, both at baseline and in response to EGFR targeted therapies, when assessed in a patient derived xenograft (PDX) mouse model 2 . The EGFRvIII + GBM cells in the tumour also took up more glucose, which is consistent with recent findings that the expression of EGFRvIII increases glyco lytic metabolism [64] [65] [66] [67] [68] . If increased glyco lysis is required to meet the increased demand for energy and carbon atoms for anabolic metabolism in GBM cells, then alterations in the levels of EGFRvIII expression might occur in response to environmental glucose levels. Clonal cooperation between EGFRvIII + and EGFRvIII -GBM cells, as has been described 26 , might provide a mechanism by which GBMs maximize their growth in response to the nutrients that are available in the microenvi ronment. Future studies are needed to assess exactly how nutrient environments shape EGFR and other RTK heterogeneity in GBM, and how RTK heterogeneity in turn modu lates tumour metabolism to maximize growth in response to the environment.
RTK heterogeneity and resistance
Radiation, cytotoxic chemotherapy and molecularly targeted treatments exert nota ble selection pressures on tumours, but how heterogeneity affects treatment response is poorly understood. In particular, the role of intratumoural RTK heterogeneity in cancer drug resistance has been difficult to deter mine, in part because tracking the fate of indi vidual tumour cells in response to treatment presents a considerable technical and logisti cal challenge. Preclinical models suggest that intratumoural RTK heterogeneity might con fer differential sensitivity to cytotoxic chemo therapies. For example, EGFRvIII promotes resistance to temozolomide and cisplatinum by, at least in part, activating mammalian tar get of rapamycin complex 2 (mTORC2) sig nalling [69] [70] [71] . Whether cytotoxic chemotherapy selects for resistant EGFRvIII + , mTORC2 acti vated tumour cells in patients with GBM who are undergoing standard treatments remains to be determined.
A number of mechanisms seem to have an important role in the development of resistance to RTKtargeted therapies, includ ing insufficient drug exposure; secondsite resistancepromoting mutations in the targeted RTK; mutations in downstream sig nalling effectors that keep the pathway acti vated; and bypass mechanisms through the amplification, mutation or upregulation of another RTK or its downstream effectors 72 . Small molecule inhibitors of RTKs pri marily bind to, and displace ATP from, a specialized domain of the receptor, thus blocking RTK activity and downstream function. Mutations that alter the binding of these drugs to the ATP pocket and/or increase the affinity of ATP versus the drug for this binding pocket prevent the tyrosine kinase inhibitors (TKIs) from blocking RTK activity 73 . Such mutations explain TKI resist ance in other forms of cancer 73 ; however, secondsite EGFR mutations have not been detected in GBM.
Genetic disruption of the tumour sup pressor gene PTEN and the phosphorylation of PTEN at Y240 limit suppression of the PI3K signalling pathway. Thus, cells with these mutations maintain PI3K signalling required for tumour growth 74, 75 and require higher doses of an EGFR TKI to turn off the crucial growth and survival signals 76 . PTEN deletion, mutation, or the phosphory lation of PTEN at Y240 show considerable
Box 1 | EGFR mutations in glioblastoma
The epidermal growth factor receptor (EGFR) plays a crucial part in the biology of many different tumours; however, its specific genetic alterations vary depending on the type of tumour. For example, somatic mutations in the EGFR kinase domain -such as L858R in exon 21, in-frame deletions in exon 19 or insertions in exon 20 -are frequently found in non-small cell lung cancer, but are rarely found in glioblastoma (GBM). By contrast, a number of deletion mutations that involve the EGFR extracellular domain (ECD) are unique to GBM. These include the EGFR type I (amino-terminal deletion), type II (exons 14-15 deletion) and type III (exons 2-7 deletion) variants (EGFRvI, vII and vIII, respectively), of which EGFRvII and EGFRvIII have been confirmed to be constitutively active and oncogenic 43, 47, 85 . Low frequency cytoplasmic tail deletion mutants, such as those found in EGFRvIV (exons 25-27 deletion) and EGFRvV (exons 25-28 deletion), are also exclusive to GBM 86 and are predicted to have attenuated ubiquitylation and degradation kinetics owing to the deletion of a CBL binding site at Y1045 (REF. 87 ). In addition, missense mutations that are located at the interface of the various domains of the EGFR ECD are another class of mutations identified in GBM and are found at ~14% frequency 7 . These mutations include R84K, A265V/D/T, P545L and G574V and are thought to favour an open, active EGFR confirmation 88, 89 , which promotes constitutive receptor activity 90 .
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intratumoural heterogeneity in GBM, and there is evidence of selection for tumour cells with Y240 phosphorylated PTEN in patients with GBM treated with the EGFR TKI erlotinib 74 .
Resistance to TKIs can also occur through the amplification or mutation of other RTKs (FIG. 5a) or by feedback upregulation of a physiologicallyregulated RTK pathway (FIG. 5b) . The observation that some EGFR amplified GBMs also contain a population of PDGFRA amplified tumour cells that are selected for in response to EGFR TKIs, at least in experimental models 51, 52, 77 , provides evi dence for one direct way in which RTK het erogeneity contributes to resistance. However, the incidence of RTK coamplification may be underestimated if nondominant amplified or mutated RTKs are present at a low level that is undetectable by nextgeneration sequencing of the bulk of a tumour.
Feedback activation of PDGFRβ in response to EGFR TKIs is another mode of EGFR TKI resistance in GBM 78 and is similar to some of the mechanisms that underlie the resistance of melanoma and colorectal cancer cells to the BRAF inhibitor vemurafinib 77, [79] [80] [81] [82] . In response to EGFR inhibition in cell lines, mouse models and patients with GBM, PDGFRβ is upregulated through trans criptional derepression 78 . The intratumoural heterogeneity of these resistancepromoting pathways remains to be determined.
Elimination of double minutes chromo somes containing EGFRvIII has recently been shown to be an unanticipated mecha nism of GBM resistance to EGFR TKIs 2 (FIG. 5c) . Singlecell studies of a GBM PDX model demonstrated that EGFRvIII expressing tumour cells were substantially more sensitive to erlotinib, and underwent apoptotic cell death in vivo upon exposure to the drug. However, a nonreversible down regulation of EGFRvIII levels, which was mediated by the elimination of EGFRvIII containing extrachromosomal DNA, was evident in tumours that were treated with erlotinib. A similar phenomenon was evi dent in patients who were treated with the EGFR TKI lapatinib. After treatment ces sation, extrachromosomal EGFRvIII levels rose, resensitizing tumour cells to erlotinib -a finding with obvious therapeutic impli cations 2 . This result indicates that intra tumoural RTK heterogeneity has a crucial role in EGFR TKI resistance in GBM.
Common themes
First and foremost, few clinical studies have been designed to enable the deter mination of whether RTK inhibitors, such as EGFR TKIs, inhibit their intended drug targets in the tumours of patients. Therefore, in the absence of detailed stud ies measuring intratumoural drug levels and target engagement, it is difficult to determine whether the failure of EGFR TKIs is simply a consequence of insuffi cient EGFR inhibition, or whether GBMs become dependent on alternative signal ling networks for growth and survival. Quantitative analysis of intratumoural lapatinib levels and measurements of EGFR phosphorylation at Y1173 by multi array immunoassays demonstrate that both intratumoural drug levels and the degree of EGFR inhibition in tumour tis sues of patients with GBM are far below the amounts that are needed to cause tumour cell death 83 . In light of the fact that PTEN deficiency might cause tumour cells to require an even larger dose of an EGFR inhibitor to achieve the same level of pathway inhibition 76 , pharmacologi cal failure might have a major role in the lack of durable efficacy that is observed in patients with GBM who have been treated with EGFR TKIs. Importantly, therapeutic resistance may still occur when the drug dose is limiting. If the intratumoural drug concentration is high enough to partially inhibit EGFR signalling, but is not high enough to cause extensive cell death, GBM cells adapt by eliminating extrachromo somal EGFRvIII DNA 2 and/or derepressing PDGFRβ 78 . Second, the preclinical data in GBM, and in other cancers, suggest that resistance to RTK targeted therapies could be partially alleviated by intermittent dosing schedules 2 . In a small study of patients with lung cancer who became resistant to gefitinib, a 'drug holiday' potently resensitized these patients to gefinitib and provided an extended period of disease control 84 . In addition, intermittent administration of TKIs might enable patients to tolerate far higher doses of a drug than the doses that are tolerated during continu ous daily administration, possibly leading to increased intratumoural drug concentra tions and better pathway inhibition in a larger fraction of tumour cells that are sensi tive to the drug. This hypothesis should be tested in clinical trials.
Last, the presence of RTK heterogeneity strongly suggests the need for mechanism based combination therapies. Consistent with Peter Nowell's prescient statement that genome instability combined with clonal selection leads to tumours bearing a population of cells that are resistant to any therapy the physician chooses 13 , Bozic and colleagues developed a mathematical model of the evolutionary dynamics of cancer. They demonstrated that, based on basal mutation rates, a minimum of dual therapy is required for disease control if no single mutation causes cross resistance to both of the drugs that are used 1 . Furthermore, for patients with a large disease burden, as is the case for many patients with GBM, three concurrent therapies are probably needed 1 
.
In line with Nowell's comments 13 , the earlier a tumour is treated then the less likely it is to be heterogeneous and to harbour resistance promoting mutations. Importantly, in the mathematical model, effective combination therapy required concurrent, not sequential, administration of the drugs. In addition, the activity of other signalling pathways that modify signalling flux through the key effec tor pathway, and/or converge on common downstream nodes, are commonly altered in cancer and can profoundly alter the activity of EGFR mutations and therefore need to be considered when combination treatments are designed 12 . Consider the current treatment for patients with GBM: following the initial surgical excision of as much of the tumour as possible, patients generally receive radia tion therapy and temozolomide and are The challenge for precision medicine Cancer is possibly the most compelling scenario for precision medicine; it is a genetic disease in which current standards of care can be ineffective. Global efforts to sequence the cancer genome were moti vated by the hope that treating patients, by matching the molecular composition of their tumour with a drug or combina tion of drugs that are optimized for their intended targets, would lead to better outcomes. Intratumoural heterogeneity, in particular the heterogeneity of amplified and mutated RTKs, presents a serious chal lenge. Singlecell RNA and DNA sequenc ing from geographically defined regions in GBM models, and from tumours of patients who have been treated with drugs alone and in combination, should provide impor tant insights into how intratumoural RTK hetero geneity alters the response of patients to targeted therapies. Indeed, preclinical models have already yielded testable and scientifically sound hypotheses about how combinations of therapies might be used to overcome resistance that is mediated by heterogeneity. These include: first, treating tumours at the point of their lowest pos sible molecular diversity, such as right after initial surgical debulking. Second, testing mechanismbased combination therapies early and upfront. Third, ensuring that the drugs achieve the sufficient intratumoural levels that are required to block their intended drug targets and affect the growth and survival of tumour cells, which could be tested by direct analysis of tumour tissue or by noninvasive imaging surrogates. Last, reconsidering dosing schedules to include intermittent dosing, which might accom modate higher levels of drug infusion, possibly with lower toxic effects than are observed with daily drug dosing. The neces sary elements with which to test the preci sion medicine hypothesis in the context of GBM are available in the form of a map of actionable driver mutations, the ability to stratify patients based on molecular pheno type and a supply of drugs that target some of the actionable driver mutations. There is also an interest among patients, oncolo gists and pharmaceutical companies in incorporating serial biopsies into the design of clinical trials to assess drug delivery and to identify the pharmacodynamic effects of drugs and the potential mechanisms of resistance against them. Incorporation of serial biopsies into clinical trials is costly and requires appropriate consent, but it may be important for developing better treatments for patients. Singleagent targeted therapies, or even strategic combinations, are likely to fail if they are not dosed, sequenced and timed in a way that is designed to overcome the challenges that are imposed by intratumoural heteroge neity and tumour evolution. An understand ing of the underpinning mechanisms will be needed to develop therapeutic strategies that are more likely to yield better outcomes for patients with GBM and other types of cancer. 
